Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter - Key Updates for March 28, 2025.
Stock Region Penny Picks Watchlist Newsletter - Key Updates for Friday, March 28, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: Please note, this newsletter is for informational purposes only and should not be considered financial advice. Always conduct your own research or consult a licensed financial adviser before making investment decisions.
$DBVT - DBV Technologies
DBV Technologies announced new financing of up to $306.9 million (€284.5 million). This funding aims to advance the Viaskin® Peanut Patch through the Biologics License Application (BLA) submission process and support its potential U.S. commercial launch, contingent upon approval. Shares are trading at $6.31 following the update.
$LXRX - Lexicon Pharmaceuticals
Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk for LX9851. This partnership could signal future collaborations and growth potential for the company. Stay tuned for further details on their plans.
$PTN - Palatin Technologies
Palatin Technologies announced positive topline results from its Phase 2 study focused on treating ulcerative colitis. Their oral melanocortin-1 receptor agonist, PL8177, showed promising outcomes, which could positively impact future clinical developments and market interest.
$QNTM - Quantum Biopharma
Quantum Biopharma has shown noteworthy improvements in its 2024 financial statements. Key highlights include robust gains in cash reserves, working capital, and operational efficiency. Furthermore, the company has eliminated material uncertainty regarding its ability to continue operating as a going concern.
$CAPT - Captivision
Captivision experienced a significant surge, with shares climbing 48% on the day to $0.63. This spike follows the unveiling of new corporate branding, signaling plans for a transformational phase of growth. Investors are watching closely for updates on this strategic shift.
$XOS - Xos Inc
Xos Inc reported disappointing quarterly earnings, with a loss of $(2.36) per share, missing analysts' expectations of $(1.19). Revenue also fell short, coming in at $11.47 million, a 35.49% decline compared to estimates of $17.79 million. This marks a decrease of 37.56% year over year in sales performance. Investors may want to approach XOS with caution.
Disclaimer: The information provided in this newsletter reflects the latest stock developments but does not guarantee future results. Stock prices are inherently volatile, and past performance is not indicative of future performance. Proceed with care in your investments.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net